The new mRNA flu shot mFlusiva is more effective. Why doctors worry Long Islanders may not get it.
The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults 50 and older, showing higher efficacy than traditional vaccines. Experts express concern that public hesitation regarding mRNA technology may limit the vaccine's uptake.
Why it matters
The introduction of mRNA technology for seasonal flu could significantly reduce hospitalizations, provided public perception does not hinder adoption.
To find mRNA vaccines can be used use for common diseases is "a great new confirmation,” said Dr. Martín Bäcker, a principal investigator at the NYU Langone-Long Island vaccine center. Credit: Debbie Egan-Chin
A newly approved flu vaccine that studies show is more effective than others may be in Long Island pharmacies in the coming weeks, but the mRNA technology it uses may unnecessarily scare some people away from using it, medical experts say.
The Food and Drug Administration Wednesday approved Moderna’s mFlusiva for people ages 50 and older after a study of more than 40,000 people ages 50 to 64 showed it is 26.6% more effective than a regular-dose traditional flu vaccine in preventing symptoms.
FDA approval is only for people 50 and older; approval for those 65 and older is provisional while further studies are conducted. Moderna also is studying mFlusiva in younger adults and adolescents.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in